The intrarenal renin-angiotensin system plays a crucial role in the regulation of renal circulation and sodium reabsorption through the activation of vascular, glomerular, and tubular angiotensin II type 1 (AT 1) receptor signaling. We previously cloned a molecule that specifically interacted with the murine AT 1 receptor to inhibit AT1 receptor signaling, which we named ATRAP (for AT 1 receptor-associated protein). Since murine ATRAP was shown to be highly expressed in the kidney, in the present study we investigated expression and distribution of human ATRAP in normal kidney and renal biopsy specimens from patients with IgA nephropathy. In the normal human kidney, both ATRAP mRNA and protein were widely and abundantly distributed along the renal tubules from Bowman's capsule to the medullary collecting ducts. In all renal tubular epithelial cells, the ATRAP protein colocalized with the AT 1 receptor. In renal biopsy specimens with IgA nephropathy, a significant positive correlation between ATRAP and AT1 receptor gene expression was observed. There was also a positive relationship between tubulointerstitial ATRAP expression and the estimated glomerular filtration rate in patients with IgA nephropathy. Furthermore, we examined the function of the tubular AT1 receptor using an immortalized cell line of mouse distal convoluted tubule cells (mDCT) and found that overexpression of ATRAP by adenoviral gene transfer suppressed the angiotensin II-mediated increases in transforming growth factor-␤ production in mDCT cells. These findings suggest that ATRAP might play a role in balancing the renal renin-angiotensin system synergistically with the AT1 receptor by counterregulatory effects in IgA nephropathy and propose an antagonistic effect of tubular ATRAP on AT1 receptor signaling.
THE RENIN-ANGIOTENSIN SYSTEM plays a critical role in the regulation of blood pressure and the maintenance of water-electrolyte metabolism. It acts through the production of the bioactive molecule angiotensin II (ANG II), exerting direct effects on the constriction of blood vessels, tubular sodium reabsorption, and the release of aldosterone. In addition, activation of the reninangiotensin system at local sites is involved in the pathogenesis of hypertension and related target organ damage, as well as the development of renal inflammatory and fibrotic disease. For these actions of ANG II at local tissue sites, the ANG II type 1 (AT 1 ) receptor is the main receptor subtype. It is distributed in a variety of tissues, including the heart, brain, artery, adrenal gland, and kidney.
The AT 1 receptor is a member of the G protein-coupled receptor superfamily, having a seven-transmembrane spanning structure which activates G proteins through the third intracellular loop and the intracellular carboxyl-terminal (C-terminal) tail of the receptor (23, 24) . The C-terminal cytoplasmic domain of the AT 1 receptor is involved in the control of AT 1 receptor internalization and plays an important role in linking receptor-mediated signal transduction to the specific biological responses to ANG II, such as hypertension, cardiovascular remodeling, and renal injury (12, 21) . To further investigate the pathophysiological molecular mechanisms of AT 1 receptor signaling, we performed a yeast two-hybrid system screening of a murine kidney cDNA library. We identified the molecule angiotensin II type 1 receptor-associated protein (ATRAP), which interacts specifically with the Cterminal cytoplasmic domain of the AT 1 receptor (4). Murine ATRAP is predicted to have a three-transmembrane domain structure and is localized to the plasma membrane and intracellular trafficking vesicles in cultured cells (1, 18, 33) . Functionally, several in vitro studies have shown that overexpression of murine ATRAP induces the internalization of the AT 1 receptor and decreases both the generation of inositol lipids and the cellular hypertrophic and proliferative responses, suggesting that ATRAP may be a negative regulator of AT 1 receptor signaling (1, 18, 33) .
With respect to a human homolog of murine ATRAP, a previous study reported the cloning of human ATRAP cDNA, with its DNA and amino acid sequences 85 and 75% identical to the murine ATRAP gene, respectively (37) . Human ATRAP was also shown to specifically interact with the C terminal of the human AT 1 receptor in vitro (37) . To date, almost all of the studies on the physiological roles of the AT 1 receptor in the kidney have been performed in rat or mouse models, and there have been few studies on the distribution and function of the AT 1 receptor in the human kidney (15) . A few previous studies showed that AT 1 receptor immunohistochemical staining was broadly observed in the blood vessels, renal tubules, and glomeruli in the normal human kidney and disclosed a marginal increase in immunostaining for the AT 1 receptor in renal tubules in biopsy specimens from patients with IgA nephropathy (3, 5, 22) .
Furthermore, at present there is no information available concerning the distribution of ATRAP in the normal and diseased human kidneys. Thus, to explore the possible pathophysiological role of ATRAP in human kidney disease, it is important to examine the expression of ATRAP in human renal tissues. Therefore, in the present study we examined the precise localization of renal human ATRAP expression at the mRNA and protein level by in situ hybridization and immunohistochemistry to determine whether the ATRAP protein coincided with the AT 1 receptor in the normal human kidney. Furthermore, we evaluated the relationship between ATRAP and AT 1 receptor protein expression, as well as the relationship between clinical variables and renal tissue expression of ATRAP and AT 1 receptor proteins in biopsy specimens from patients with IgA nephropathy.
METHODS
Materials. ANG II was purchased from Sigma. The AT1 receptorspecific blocker candesartan (CV11974) and ANG II type 2 receptor (AT 2 receptor)-specific blocker PD123319 were kindly supplied by Takeda Pharmaceutical Company and the Parke-Davis division of Pfizer, respectively.
Cell culture and transient transfection. The immortalized cell line H9c2, which expresses the endogenous AT 1 receptor, was cultured as described previously (33) . The human ATRAP cDNA expression plasmid (PCMV6XL5), the NH 2-terminal heme agglutinin (HA) epitope-tagged murine ATRAP in pcDNA3 (pc-HA-mATRAP), or the empty vector pCAGGS plasmid was transiently transfected into H9c2 cells according to the Lipofectamine 2000 protocol (Invitrogen) (4). Forty-eight hours after the transfection, whole cellular extracts were prepared from the transfected cells (18) .
Mouse distal convoluted tubule (mDCT) cells were kindly provided by Dr. Peter A. Friedman (University of Pittsburgh School of Medicine, Pittsburgh, PA). The cells had been previously isolated and functionally characterized as described (9) . Cells were grown on 100-mm dishes (Corning) in DMEM/HAM F-12 media (1:1, SigmaAldrich) supplemented with 5% heat-inactivated fetal calf serum (MBL), 2 mM L-glutamine (GIBCO), 0.5 mg/ml streptomycin, 0.5 mg/ml penicillin, and 1 mg/ml neomycin (GIBCO), in a humidified atmosphere of 5% CO 2-95% air. For the stimulation with ANG II, mDCT cells were subcultured in 6-cm-diameter dishes (1.5 ϫ 10 5 / ml), incubated overnight, and further incubated in serum-free medium for 24 h.
Preparation of normal human renal tissue and biopsy specimens with IgA nephropathy. Normal, uninvolved human male renal tissue (n ϭ 1) obtained from resected renal carcinoma kidneys was perfusion-fixed with 4% paraformaldehyde and used for in situ hybridization and immunohistochemistry. Needle renal biopsy specimens were also obtained from 22 patients with IgA nephropathy and were used for immunohistochemistry. The diagnosis of IgA nephropathy was confirmed by pathological evaluation of renal biopsy specimens, such as light microscopy, electron microscopy, and immunofluorescence staining. No patients received steroids or immunosuppressive drugs before renal biopsy. The following clinical parameters were examined at the time of needle renal biopsy: age, gender, body mass index, blood pressure, serum creatinine, total protein, urinary protein, and estimated glomerular filtration ratio (eGFR). We calculated eGFR with an application of a revised equation for the Japanese population: eGFR (ml·min Ϫ1 ·1.73 m Ϫ2 ) ϭ 194 ϫ serum creatinine Ϫ1.094 ϫ age Ϫ0.287 ϫ 0.739 (if female) (19) . The study protocol was approved by the Human Ethics Review Committee of Yokohama City University Graduate School of Medicine, and written informed consent was obtained from each patient.
In situ hybridization. In situ hybridization was performed as described previously (34) . After fixation, the normal human renal tissue (n ϭ 1) was embedded in paraffin and sectioned. The riboprobes were generated complementary to the human ATRAP cDNA fragments (981 bases, ϩ132 to ϩ1112). Digoxygenin-labeled antisense and sense probes were prepared by the transcription of linearized human ATRAP cDNA in a pcDNA3.1 vector (Invitrogen) using a digoxygenin RNA labeling kit (Roche, Basel, Switzerland). Hybridized digoxygenin-labeled probes were detected using anti-digoxygenin-alkaline phosphatase conjugate. The probe was visualized using 4-nitroblue tetrazolium chloride and 5-bromo-4-chloro-3-indolylphosphate.
Production of rabbit polyclonal anti-human ATRAP antibody. A 16-amino acid synthetic peptide corresponding to amino acids 144 -158 of the C-terminal tail of human ATRAP was produced using standard solid-phase peptide synthesis techniques. Analysis using the BLAST computer program showed no significant overlap of the immunizing peptide with any known eukaryotic protein. The peptide was purified, conjugated, and injected five times intradermally into rabbits at 2-wk intervals for the production of the polyclonal antiserum. The rabbits developed enzyme-linked immunosorbent assay titers Ͼ1:128,000 before exsanguination. The selectivity of the antiserum was validated by the recognition of the PCMV6XL5-transfected H9c2 cells by Western blot analysis. Anti-ATRAP polyclonal antibodies were affinity-purified. This study was performed in accordance with the National Institutes of Health guidelines for the use of experimental animals. All of the animal studies were reviewed and approved by the animal studies committee of Yokohama City University.
SDS-PAGE and immunoblotting.
Whole cellular extracts (20 g/ lane) from H9c2 cells were subjected to SDS-PAGE and transferred to polyvinylidene difluoride membranes (Millipore). The membranes were incubated with either 1) human ATRAP antibody diluted to 1:1,000; 2) human ATRAP antibody preabsorbed with a 10-fold excess of the peptide used to generate the antibody; or 3) murine ATRAP antibody (34) . Sites of antibody-antigen reaction were visu- Fig. 2 . Specificity of purified polyclonal anti-human ATRAP antibody. H9c2 cells were transfected with the human ATRAP cDNA expression plasmid (Human ATRAP) or an empty pCAGGS vector (Empty), and Western blot analysis was performed using an anti-human ATRAP antibody (Anti-human ATRAP Ab). The specificity of the anti-human ATRAP antibody was confirmed by preabsorption of the anti-human ATRAP antibody with the competing antigenic peptide (preabsorption ϩ). As a reference, H9c2 cells were also transfected with the NH2-terminal heme agglutinin (HA) epitopetagged murine ATRAP in pcDNA3 (Murine HA-ATRAP), and Western blot analysis was performed using the anti-murine ATRAP antibody (Antimurine ATRAP Ab). alized by enhanced chemiluminescence (Amersham Biosciences). The images were analyzed with an LAS-3000 imaging system (Fuji Film, Tokyo, Japan).
Immunohistochemistry. Immunohistochemistry was performed essentially as described previously (13, 34) . After fixation, the renal tissues were embedded in paraffin, and sectioned at 4-m thickness. The sections were treated for 60 min with 10% normal goat serum in phosphate-buffered saline and blocked for endogenous biotin activity using an Avidin/Biotin Blocking kit (Vector Laboratories). For the study of ATRAP, the sections were incubated with one of the following: 1) ATRAP antibody diluted at 1:100; 2) ATRAP antibody preabsorbed with a 10-fold excess of the peptide used to generate the antibody; or 3) nonimmune rabbit IgG. For the study of AT 1 receptor, the sections were incubated with 1) AT1 receptor antibody [AT1 (N-10), sc-1173, Santa Cruz Biotechnology, Santa Cruz, CA] diluted at 1:100; or 2) nonimmune rabbit IgG. The characterization and specificity of the anti-AT 1 receptor antibody was described previously (34) . For the study of specific nephron markers, the sections were incubated with either 1) aquaporin-1 antibody (ab9566, Abcam) diluted at 1:100; 2) calbindin D-28K antibody (C9848, SigmaAldrich) diluted at 1:3,000; 3) Tamm-Horsfall glycoprotein antibody (sc-20631, Santa Cruz Biotechnology) diluted at 1:100; or 4) nonimmune rabbit IgG. The sections were incubated for 60 min with biotinylated goat anti-rabbit IgG or biotinylated goat anti-murine IgG (SAB-PO kit, Nichirei, Tokyo, Japan), blocked for endogenous peroxidase activity by incubation with 0.3% H 2O2 for 20 min, treated for 30 min with the streptavidin and biotinylated peroxidase (DAKO, Heidelberg, Germany), and then exposed to diaminobenzidine. The sections were counterstained with hematoxylin, dehydrated, and mounted.
Continuous high-resolution and high-magnification immunohistochemical images were obtained by using a BZ-9000 (KEYENCE, Osaka, Japan), and immunoreactivity was semiquantitatively evaluated in a blind manner. Examination was performed using a microscope with ϫ400 magnification (Olympus, Tokyo, Japan) and an integrated digital camera system (Olympus). Image Pro-plus computer image-analysis software (Media Cybernetics, Bethesda, MD) was used to analyze the brown staining pixel density and to quantify the protein levels, as described previously (6, 10, 14, 28, 39) .
To further assess the colocalization of the AT1 and ATRAP proteins, 4-m-thick mirror image paraffin sections were subjected to immunohistochemistry. Mirror image immunohistochemical staining was performed as described above. To demonstrate colocalization in the identical nephron section, ATRAP was detected by peroxidase-3-amino-9-ethylcarbazole and AT1 receptor by alkaline phosphatasenitroblue tetrazolium.
Preparation of recombinant adenoviral vectors and gene transfer. Adenoviral vectors were prepared using cDNAs coding for the NH 2-terminal HA epitope-tagged ATRAP (Ad.HA-ATRAP) and bacterial ␤-galactosidase (Ad.LacZ) using a commercially available system (Adeno X Expression System, Clontech), and the virus titer was determined with a plaque assay (33) . For the adenoviral gene transfer experiments, mDCT cells were subcultured in 6 cm-diameter dishes (5 ϫ 10 4 /ml), incubated overnight, infected with recombinant adenovirus (Ad.HA-ATRAP or Ad.LacZ) at 50 multiplicity of infection for 24 h, and further incubated in a serum-free medium for an additional 24 h. Then, the cells were treated with ANG II (10 Ϫ6 M) for the indicated time, and subsequently harvested for analysis.
ELISA of transforming growth factor-␤. ELISA using conditioned medium derived from the cultured dishes was performed to examine the effect of candesartan, PD123319, or ATRAP on ANG II-mediated transforming growth factor-␤ (TGF-␤) secretion from mDCT cells, essentially as described previously (30) . The total TGF-␤ released into the media was determined with an ELISA system by Immuno Mini NJ-2300 (Nalge Nunc International) and Quantikine TGF-␤1 (MB100B, R&D Systems), according to the manufacturer's instructions.
Statistical analysis. Data are expressed as means Ϯ SE. Statistical significance was determined using an unpaired Student's t-test, with P Ͻ 0.05 being considered statistically significant.
RESULTS

Distribution of ATRAP mRNA in normal human kidney.
We first examined the expression and distribution of ATRAP mRNA in normal human renal tissue sections from a patient with renal cell carcinoma without other obvious chronic kidney disease by in situ hybridization using a human ATRAP antisense cRNA probe. In the glomerular region, expression of human ATRAP mRNA was observed in Bowman's capsule, podocytes, and mesangial cells (Fig. 1A) . In the cortical tubular region, a high level of ATRAP mRNA was observed in the proximal convoluted tubules (PCT), DCT (Fig. 1B) , proximal straight tubules (PST), and cortical collecting ducts (CCD) (Fig. 1C) . In the medullary region, positive staining was observed in the medullary collecting ducts (MCD), while a lower level of ATRAP mRNA was observed in the thin limbs (TL) and thick ascending limbs (TAL) (Fig. 1D) . The ATRAP mRNA staining was weak in the vascular smooth muscle cells of the vasculature, including the interlobular arteries (Fig. 1E) . No labeling of human ATRAP mRNA was found in the negative control sections that were hybridized with the sense probe ( Fig. 1F which is the consecutive section of Fig. 1A) .
Production of anti-human ATRAP antibody and validation of specificity. We developed a specific polyclonal antibody against human ATRAP. Western blot analysis of human ATRAP cDNA-transfected H9c2 cells revealed that the antiserum for human ATRAP recognized a prominent band of 17 kDa, which was consistent with the predicted molecular weight of human ATRAP, and also with the murine ATRAP band (ϭ 18 kDa) derived from murine ATRAP cDNA-transfected cells, which was detected by an anti-murine ATRAP antibody (Fig. 2) . This band was not observed when the antiserum was replaced with the preimmune serum (data not shown), or when empty vector pCAGGS-transfected H9c2 cells were used instead of human ATRAP-transfected cells (Fig. 2) . These data indicate that the anti-human ATRAP antibody is able to recognize the human ATRAP protein specifically.
Distribution of ATRAP protein in normal human kidney. We next examined the expression and distribution of ATRAP protein in the normal human kidney of the same patient, who had been analyzed for the distribution of ATRAP mRNA expression, by immunohistochemistry using the anti-human ATRAP antibody. In the renal cortex, a relatively high level of ATRAP immunoreactivity was observed in the tubular nephron segments (Fig. 3A) , and a lower level of ATRAP immunostaining was detected in Bowman's capsule, podocytes, and mesangial cells in the glomerulus (Fig. 3A) . No significant immunoreactivity of the ATRAP protein was found in the negative control sections incubated with preabsorption of the antihuman ATRAP antibody along with the competing antigenic peptide (Fig. 3B ) and incubated with nonimmune rabbit IgG (data not shown).
To definitively identify the ATRAP immunostaining sites in the tubular segments, consecutive sections were stained for ATRAP and markers specific for the tubular segments. We used a polyclonal antibody against aquaporin-1, which is specifically expressed in the proximal tubules (20, 25) , a monoclonal antibody against calbindin-D, a calcium-binding protein expressed primarily in the DCT and connecting tubules (CNT) (17, 35) , and a polyclonal antibody against the TammHorsfall protein, which is specifically expressed in the TAL. In the renal cortex, a relatively high level of ATRAP immunostaining was detected in the PCT and DCT and a lower level was observed in the CCD (Fig. 3D) . In the renal medulla, a relatively high level of ATRAP immunoreactivity was observed in the PST (Fig. 4, A and D) , with a lower level detected in the MCD and TAL, and a weak level in the TL (Fig. 4A) . In vascular smooth muscle cells, including the interlobular arteries, ATRAP immunostaining was very weak (Fig. 4G) .
Colocalization of ATRAP with the AT 1 receptor in human normal kidney. We also examined the intrarenal distribution of human AT 1 receptor protein by immunohistochemistry using the anti-AT 1 receptor antibody. The results of immunohistochemistry using the AT 1 receptor antibody revealed intense staining in Bowman's capsule (Fig. 3C) , PCT, PST, DCT, CCD, TAL, and MCD ( Fig. 3E and Fig. 4, B and E) , and moderate staining in the vascular smooth muscle cells (of the vasculature), including the interlobular arteries (Fig. 4H) . A lower level of AT 1 receptor immunostaining was also detected in podocytes and mesangial cells in the glomeruli (Fig. 3C) and TL (Fig. 4B) . In the consecutive sections stained for the ATRAP and AT 1 receptor, all of the ATRAP-immunopositive tubular nephron segments expressed the AT 1 receptor (Fig. 3,  D and E, Fig. 4, A, B, D , and E; summarized in Table 1 ). The results of further immunohistochemical analysis of mirror sections which were stained for ATRAP and the AT 1 receptor also disclosed a significant colocalization of the proteins in the glomerulus and especially in the tubular nephron segments (Fig. 5) .
Relationship between ATRAP and AT 1 receptor expression in human needle renal biopsy specimens of IgA nephropathy. The intrarenal expression and distribution of the ATRAP and AT 1 receptor genes were evaluated on needle renal biopsy specimens from 22 patients with IgA nephropathy by immunohistochemistry (Fig. 6) . Since the densities of ATRAP and AT 1 receptor immunostaining were extremely high and likely to lie outside the range limit in 1 patient (data not shown), we excluded the data of this patient from further analysis and evaluated a potential correlation between ATRAP and AT 1 receptor gene expression patterns in the 21 other patients with IgA nephropathy. This relationship is thought to be of interest because ATRAP and the AT 1 receptor have opposite effects mediated by ANG II, i.e., opposite effects with regard to renal tissue damage.
The results showed a positive relationship between ATRAP and AT 1 receptor immunostaining in the glomerular region (r ϭ 0.79, P Ͻ 0.01) (Fig. 7A) . There was also a significant correlation in the tubulointerstitial region (r ϭ 0.92, P Ͻ 0.01) of the renal tissues with IgA nephropathy (Fig. 7B) . We further examined a possible sex difference in the relationships between ATRAP and AT 1 receptor immunostaining. In male patients with IgA nephropathy (n ϭ 12), although the relationship between ATRAP and AT 1 receptor immunostaining did not reach significance in the glomerular region (r ϭ 0.60, P ϭ 0.09) (Fig. 8A) , there was a significant relationship in the tubulointerstitial region (r ϭ 0.82, P Ͻ 0.01) (Fig. 8B) . On the other hand, there were significant correlations between ATRAP and AT 1 receptor immunostaining in both the glomerular (r ϭ 0.90, P Ͻ 0.01) (Fig. 8C ) and tubulointerstitial (r ϭ 0.94, P Ͻ 0.01) (Fig. 8D ) regions in female patients with IgA nephropathy (n ϭ 9).
Clinical variables and ATRAP and AT 1 receptor expression in human needle renal biopsy specimens of IgA nephropathy.
Finally, we examined the relationship between clinical variables and renal ATRAP and AT 1 receptor immunostaining. The clinical parameters examined included age, body mass index, mean blood pressure, serum creatinine, total protein, urinary protein, and eGFR (Table 2 ). There was a significant positive relationship between eGFR and tubulointerstitial ATRAP immunostaining (r ϭ 0.44, P ϭ 0.046) in the needle renal biopsy specimens of IgA nephropathy (Fig. 9D) . However, no significant correlation was observed between any other variables and the staining of the two proteins (Fig. 9 , A-C; data not shown).
Endogenous expression of ATRAP and AT 1 receptor in renal distal tubular cells. The results of previous studies as well as the present study showed that renal ATRAP as well as the AT 1 receptor is expressed abundantly in the distal and proximal tubules in the mouse and human kidney (34) . Thus, to examine the functional role of tubular ATRAP, we used mDCT cells (8) . These cells have been shown to have the phenotype of a polarized tight junction epithelium with morphological and functional features retained from the parental cells (8) . The mDCT cells expressed the endogenous AT 1 receptor and ATRAP mRNA, as detected by RT-PCR (Fig. 10A) . Western blot analysis also recognized the endogenous AT 1 receptor and ATRAP protein in mDCT cells, respectively (Fig. 10B ). These results demonstrate that the ATRAP and AT 1 receptor proteins are endogenously expressed in mDCT cells.
Effects of ANG II and adenoviral transfer of recombinant ATRAP on TGF-␤ secretion from renal distal tubular cells.
ANG II has been implicated in the development of renal pathological processes due to its induction of the synthesis of the profibrotic cytokine TGF-␤ in the renal tubules (2, 11) , which is associated with subsequent alterations in cell growth and matrix production (29, 38) . In mDCT cells, activation of TGF-␤ secretion was dependent on the concentration of ANG II (Fig. 11A) , and there was a time-dependent increase in TGF-␤ secretion from mDCT cells into the medium induced by ANG II treatment (Fig. 11B) . While pretreatment of mDCT cells with candesartan (10 Ϫ5 M) abolished the stimulatory 
DISCUSSION
The renin-angiotensin system is a well-coordinated hormonal cascade which critically regulates cardiovascular and renal homeostasis by maintaining fluid and electrolyte balance. In addition, stimulation of the renin-angiotensin system, particularly activation of AT 1 receptor signaling at local tissue sites, plays an important role in the pathophysiology of cardiovascular and renal disease. We previously cloned ATRAP as a novel molecule which interacts with the AT 1 receptor and showed that ATRAP suppressed ANG II-induced pathological responses by inducing constitutive AT 1 receptor internalization (4, 18) . Thus ATRAP is suggested to be a potent counterregulator of the AT 1 receptor. We previously showed that ATRAP is expressed in a variety of murine tissues, as is the AT 1 receptor (34) . Because activation of the AT 1 receptor at local tissue sites is thought to be a pivotal step in cardiovascular and renal injury, ATRAP has emerged as a potential inhibitor of tissue AT 1 receptor activation (24, 32) .
There are previous reports on the human intrarenal reninangiotensin system showing abundant expression of the human AT 1 receptor in the glomeruli, tubules, and vasculature and its upregulation in the renal tubules in IgA nephropathy (3, 5, 22) . However, to date there has been no report on renal expression and distribution of ATRAP other than in the murine kidney (34) . The role and significance of ATRAP in the regulation of the renin-angiotensin system in human renal tissue have yet to be elucidated. Moreover, the clinical and pathological factors modulating the expression of ATRAP in the human kidney Values are means Ϯ SE; n ϭ 21, 12 men and 9 women. eGFR, estimated glomerular filtration rate.
remain to be determined. Along these lines, a polyclonal anti-human ATRAP antibody was developed proven to be useful for the analysis of ATRAP protein expression in human tissue. Employing in situ hybridization and immunohistochemistry for ATRAP within human kidney sections, we showed for the first time that renal ATRAP expression, at both the mRNA and protein level, was widely and abundantly distributed in the renal tubules from Bowman's capsule to the MCD, with the relative abundance similar in each nephron segment. Furthermore, expression of ATRAP mRNA and protein was also detected in the glomerulus and vasculature, although the signals for both were comparatively weak in these areas.
With respect to the intrarenal distribution of the AT 1 receptor, specific immunoreactivity was observed in the vasculature and along the nephron segments, which was consistent with the findings of a previous study performed using normal kidney sections (22) . From the immunohistochemical results of the present study, all ATRAP-immunopositive tubules from Bowman's capsule to the MCD expressed the AT 1 receptor in the consecutive sections which also stained for ATRAP. Thus the results of the present study demonstrate that human ATRAP is expressed along almost the entire nephron segment, as is the AT 1 receptor, with ATRAP abundantly expressed in the renal tubules. However, there was some dissociation between the two proteins in the pattern of intrarenal distribution. In particular, at the protein level, renal AT 1 receptor expression was more abundant than ATRAP expression in the vasculature. Previous studies have indicated that pathological vascular remodeling of the small renal arteries is critically involved in the development of hypertension and renal damage (7, 16, 31) . They have also suggested that the protective effects of reninangiotensin system inhibitors on the renal vasculature are, at least in part, responsible for prevention and amelioration of hypertension and renal injury (7, 16, 31) .
On the other hand, the renal tubulointerstitial AT 1 receptor is also reported to play an important role in the regulation of sodium handling and epithelial-mesenchymal transition, as well as the pathogenesis of hypertension and renal fibrosis (15, 26, 27, 29) . The results of the present study showed abundant renal tubular ATRAP expression in addition to tubular AT 1 receptor expression, while ATRAP expression in the vasculature was low. Interestingly, a significant correlation was detected between ATRAP and AT 1 receptor expression in the tubulointerstitial region, mainly in the tubular segments and not the vasculature, of the human needle renal biopsy specimens from patients with IgA nephropathy (Figs. 7 and 8) . A previous study reported a similar synergistic expression of angiotensin-converting enzyme (ACE) and ACE2, a counterregulator of ACE in generating ANG II as one of the organprotective factors in human renal tissue (36) . Thus we consider this finding to be important in the effort to elucidate the mechanisms of the renal interplay between the AT 1 receptor and ATRAP and for establishing the role of renal ATRAP as a counterregulator of the AT 1 receptor.
In particular, the interpretation of the results showing a positive but not negative correlation between ATRAP and the AT 1 receptor in the diseased kidney might be controversial. The present results suggest that ATRAP protein expression does not actively alter the status of the renal renin-angiotensin system. We speculate that AT 1 receptor and ATRAP protein expression may be regulated in a coordinated manner, or synergistically, which is mediated via the local activation of AT 1 receptor signaling. A notable point here is that not only the AT 1 receptor, but also ATRAP, may be responsible for determination of the renal activity of AT 1 receptor signaling at the local tissue sites, with a coordinated expression of ATRAP exerting a countereffect against AT 1 receptor activity by constitutive stimulation of AT 1 receptor internalization. It is suggested that the role of ATRAP must be taken into consideration for the pathogenesis of renal tissue injury.
However, since the present study is a cross-sectional study examining the relationship between ATRAP and the AT 1 receptor in IgA nephropathy, but not a prospective study to examine effects of intervention to affect AT 1 receptor signaling, the exact mechanism for this regulation is not clear. We were not able to determine whether the AT 1 receptor influences ATRAP expression in the kidney at this stage. Additional studies with repeated biopsies and intervention in AT 1 receptor signaling such as by means of AT 1 receptor-specific blockers are needed to elucidate the mechanism of the relationship between ATRAP and the AT 1 receptor in the kidney of IgA nephropathy.
We also tested the possibility that the clinical characteristics are substantially related to renal ATRAP expression. Indeed, semiquantitative analysis of the relationship between the clin- ical variables and the renal AT 1 receptor and ATRAP immunostaining revealed ATRAP protein expression to be significantly and positively correlated with eGFR. The other parameters of renal function, e.g., urinary protein and serum creatinine, were not significantly associated with ATRAP protein expression (Fig. 7) . The eGFR values may reflect disease (IgA nephropathy)-induced deterioration of renal function. Whether eGFR or renal ATRAP protein expression is the cause remains to be determined. It seems that the eGFR status should be the cause of changes in renal ATRAP protein expression; however, this is difficult to address, and additional studies, i.e., repeated biopsies and/or prospective follow-up, are needed.
Furthermore, since we examined the expression and distribution of ATRAP mRNA and protein in normal human renal tissue sections from one patient with renal cell carcinoma without other obvious chronic kidney disease, a limitation of the present study is that it did not examine a possible association between AT 1 receptor and ATRAP in the normal human kidney. Another limitation is the lack of immunofluorescent colocalization analysis with double staining of ATRAP and the AT 1 receptor using a multiple fluorolabeling method and confocal laser microscopy. Nevertheless, these results suggest that the decrease in eGFR, as a strong cardiovascular risk factor for "cardio-renal syndrome," might influence renal ATRAP expression and thereby play a critical role, presumably, affecting AT 1 receptor signaling in renal tissues.
Finally, to investigate the function of tubular ATRAP in vitro, we used an immortalized cell line (mDCT cells). These cells have been shown to have a polarized tight junction epithelium with morphological and functional features retained from parental cells, and they have been previously characterized at the molecular level with respect to their responsiveness to various hormones and agents (8, 9) . In the present study, ATRAP was abundantly expressed and widely distributed along the renal tubules, including the DCT cells. Furthermore, in all tubular cells, including DCT cells, ATRAP protein was colocalized with AT 1 receptor protein, based on immunohistochemical analysis. Since previous studies showed that ATRAP inhibited ANG II-induced pathological responses of cardiovascular cells by promoting a constitutive internalization of the AT 1 receptor (24, 32), we examined whether renal tubular ATRAP antagonizes the pathological activation of the tubular AT 1 receptor using mDCT cells. The results showed that the overexpression of ATRAP suppresses the AT 1 receptor-mediated activation of TGF-␤ production in response to ANG II stimulation, thereby suggesting that tubular ATRAP is an endogenous suppressor of the activation of tubular AT 1 receptor signaling.
In summary, the results of the present study demonstrate the abundant expression of ATRAP mRNA and protein and their distribution in the human kidney. ATRAP is broadly distributed along the nephron, with a substantial colocalization of ATRAP and the AT 1 receptor. The results using human needle renal biopsy specimens of IgA nephropathy show a significant relationship between renal ATRAP and AT 1 receptor protein levels, and renal ATRAP protein expression appears to be influenced by renal functional status. Furthermore, the findings obtained by in vitro experiments using renal distal tubular cells also showed the functional significance of renal tubular AT 1 receptor signaling, as well as the antagonistic effect of tubular ATRAP on this signaling. These findings suggest that in addition to the AT 1 receptor, ATRAP, a newly emerging component of the renin-angiotensin system, is likely to play a role in balancing the renal renin-angiotensin system by counterregulatory effects, which in turn may be confounded by the presence of chronic kidney disease.
